| 148.56 4.44 (3.08%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 196.03 |
1-year : | 228.96 |
| Resists | First : | 167.83 |
Second : | 196.03 |
| Pivot price | 141.29  |
|||
| Supports | First : | 142.57 |
Second : | 126.96 |
| MAs | MA(5) : | 138.42 |
MA(20) : | 144.48 |
| MA(100) : | 161.64 |
MA(250) : | 184.93 |
|
| MACD | MACD : | -5 |
Signal : | -5.8 |
| %K %D | K(14,3) : | 59.5 |
D(3) : | 39.7 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 266.66 | Low : | 126.96 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BGNE ] has closed below upper band by 27.2%. Bollinger Bands are 26.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 152.85 - 153.38 | 153.38 - 153.86 |
| Low: | 144.65 - 145.33 | 145.33 - 145.95 |
| Close: | 147.49 - 148.43 | 148.43 - 149.29 |
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
BeiGene (NASDAQ:BGNE) Trading 4.3% Higher After Analyst Upgrade - MarketBeat
Wed, 24 Apr 2024
Evaluating BeiGene: Insights From 6 Financial Analysts - BeiGene (NASDAQ:BGNE) - Benzinga
Tue, 23 Apr 2024
BeiGene (NASDAQ:BGNE) Shares Gap Up to $130.94 - MarketBeat
Tue, 23 Apr 2024
EU regulators approve BeiGene's tislelizumab for lung cancer (NASDAQ:BGNE) - Seeking Alpha
Tue, 23 Apr 2024
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners - Yahoo Finance
Sun, 21 Apr 2024
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 763 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 48 (%) |
| Shares Short | 1,730 (K) |
| Shares Short P.Month | 1,930 (K) |
| EPS | -8.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.83 |
| Profit Margin | -35.9 % |
| Operating Margin | -60.7 % |
| Return on Assets (ttm) | -12.4 % |
| Return on Equity (ttm) | -22.3 % |
| Qtrly Rev. Growth | 66.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 23.54 |
| EBITDA (p.s.) | -10.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,160 (M) |
| Levered Free Cash Flow | -1,270 (M) |
| PE Ratio | -17.59 |
| PEG Ratio | -0.1 |
| Price to Book value | 4.39 |
| Price to Sales | 6.31 |
| Price to Cash Flow | -13.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|